Abstract
Introduction
There are over 300,000 species of extant seed plants around the globe.
1
About 60% of plants have found medicinal use in the post-Neolithic human history. Nowadays, people collect plants for medicinal use not only from the wild but also through artificial cultivation, which is an indispensable part of human civilization. There are over 10,000 medicinal plant species in China, accounting for ~87% of the Chinese materia medica (CMM).
2
Medicinal plants are also essential raw materials of many chemical drugs, eg, the blockbuster drugs for antimalarial and anticancer therapy. Currently, more than one-third of clinical drugs are derived from botanical extracts and/or their derivatives. Unfortunately, most medicinal plants have not been domesticated, and currently there is no toolkit to improve their medicinal attributes for better clinical efficacy. Immoderate harvesting has led to supply crisis of phytomedicine, exemplified by the taxane-producing
Evolution of Genome, Gene, and Genotype
Genome sequencing
The genomic studies of medicinal plants lag behind those of model plants and important crop plants. The genome sequences encompass essential information of plant origin, evolution, development, physiology, inheritable traits, epigenomic regulation, etc., which are the premise and foundation of deciphering genome diversity and chemodiversity (especially various secondary metabolites with potential bioactivities) at the molecular level. High-throughput sequencing of medicinal plants could not only shed light on the biosynthetic pathways of medicinal compounds, especially secondary metabolites, 4 and their regulation mechanisms but also play a major role in the molecular breeding of high-yielding medicinal cultivars and molecular farming of transgenic medicinal strains.
A few principles should be considered when selecting medicinal plants for whole-genome sequencing projects: first, source plants of well-known and expensive CMMs or important chemical drugs that are in heavy demand, eg,
As there is a lack of comprehensive molecular genetic studies on most medicinal plants, it is vital to have some preliminary genome evaluations done before whole-genome sequencing. First, DNA barcoding techniques
13
could be used to authenticate the candidate species; second, karyotypes should be determined by observing metaphase chromosomes; last, flow cytometry and pulsed-field gel electrophoresis (PFGE)9,14 could be used to determine the ploidy level and genome size. For example, flow cytometry was used to determine the genome size of four

Technology roadmap of RAD-Seq and its utility in population evolution and genetic map.
The whole-genome sequencing platform is chosen based on the budgetary resources and the preliminary evaluation of candidate genomes. 2 The GS FLX or Illumina HiSeq 2500 platform might be suitable for a small, simple genome. However, the majority of the plant genomes are complex, which means they are diploid/polyploidy genomes with >50% repeat sequences and >0.5% heterozygosity. Two or more sequencing platforms could be combined for shotgun and paired-end sequencing, while large insert libraries, eg, BAC (bacterial artificial chromosome), 9 YAC (yeast artificial chromosome), 18 and Fosmid, 14 can be constructed for sequencing; then a sophisticated bioinformatics software19–23 can be used for sequence quality control and assembly. For instance, GS FLX and shotgun sequencing can be used for the initial genome assembly to generate 454 contigs, and then the paired-end sequencing data from the Illumina HiSeq or SOLiD platform used to determine the order and orientation of 454 contigs, thus generating scaffolds. Next, Illumina HiSeq or SOLiD data are used to fill the gap between some contigs. These steps streamline the genome sequencing pipeline as a whole.
The genetic map and physical map are fundamental tools for the assembly of the complex plant genomes and functional genomics research. The genetic linkage map of
Chloroplast genome evolution
Chloroplast (cp) is responsible for photosynthesis, and its genome sequences have versatile utility in evolution, adaptation, and robust growth of most medicinal plants. The substitution rate of the cp nucleotide sequence is 3–4 times faster than that of the mitochondria (mt) sequence, 5 implicating more uses of the former in inferring both interspecific and intraspecific evolutionary relationships.5,28–33
The genus
The monocot family Orchidaceae, which is evolutionarily more ancient than asterids and rosids, is one of the largest angiosperm families, including many medicinal, horticultural, and ornamental species. Orchid phytometabolites display antinociceptive,
35
antiangiogenic,
36
and antimycobacterial
37
activities, among others. In south Asia, orchid bulb is used for the treatment of asthma, bronchitis, throat infections, dermatological infections, and also as a blood purifier.
38
Sequencing the complete cp genomes of the medicinal plant
The monocot genus
Medicinal plant diversity, comprising genetic diversity, medicinal species diversity, ecological system diversity, and so on,
48
results from the intricate interactions between the plant and its environment, and thus is profoundly influenced by the ecological complex and the relevant versatile ecological processes. The effects of the evolutionary processes have to be taken into full consideration when explaining the link between climatic/ecological factors and medicinal plant diversity, especially that in a region where there is strong, uneven differentiation of species. A distinguished example is the “sky islands” of southwest China,
49
where the extraordinarily rich resources of medicinal plants rose and thrived during the Quaternary Period. To date, many medicinal tribes and genera, eg,
Mitochondria genome evolution
Some fundamental evolution concepts, such as lateral gene transfer, are bolstered by the inquiry of the origin of mt, while plants are especially useful in elucidating the mechanisms of cytonuclear coevolution. Although the gene order of the mt genome might evolve relatively fast in land plants, the substitution rate of its nucleotide sequence is merely 1/100 of that of animal sequence. 48 Therefore, the mt genome sequence is less useful than the cp genome in inferring the phylogenetic relationship of medicinal species. 57 Notwithstanding, analysis of the genome sequence is still able to contribute to the knowledge on the evolution of the mt genome. Moreover, the terpene synthase has been found in mt, 58 highlighting its utility in secondary metabolism.
Nuclear genome evolution
The whole cp genome dataset is not enough to elucidate the phylogenetic relationship of groups undergoing rapid radiation, eg, Zingiberales. 59 The cp genome is equivalent to one gene locus, thus it only represents one fulfillment to the coalescent random processes and cannot be used with confidence to reconstruct the evolution history of the populations. Most genetic history of any medicinal plant hides in the nr genome.
High-throughput sequencing and the relevant bioinformatics advances have revolutionized contemporary thinking on nuclear genome/transcriptome evolution and provided basic data for further breeding endeavor.
Whole-genome sequencing has been implemented in the representative species of some plant families/genera (Fig. 2), eg,

Examples of the phylogeny and genome duplication history of core eudicots.
One of the milestone breakthroughs is the successful sequencing and assembly of the complex heterozygous genome. The heterozygous genome of

Categories of transposable elements predicted in the orchid genome (according to Ref. 23).
More than 40 plant genomes have been sequenced, representing a diverse set of taxa of agricultural, energy, medicinal, and ecological importance.19–23 Gene family members are often inferred from DNA sequence homology, but deeper insights into evolutionary processes contributing to gene family dynamics are imperative. In a comparative genomics framework, multiple lines of evidence can be generated by gene synteny, sequence homology, and protein-based hidden Markov modeling (HMM) to extract homologous super-clusters composed of multi-domain resistance (R)-proteins of the NB-LRR (nucleotide binding-leucine rich repeat) type, which are involved in plant innate immunity.
61
Twelve eudicot plant genomes were screened to assess the intra and interspecific diversity of R-proteins, where 2,363 NB-LRR genes were found. Half of the R-proteins have tandem duplicates, and 22% of gene copies are left from ancient polyploidy events (ohnologs, whole-genome duplication duplicates). The positive Darwinian selection and major differences in molecular evolution rates (
The estimated upper limit of extant plants is ~450,000, indicating the potentially enormous biological space. Multiple and recurrent genome duplications during plant evolution result in the generation of novel biosynthetic pathways of diverse medicinal compounds, which are frequently involved in plant defense and disease resistance, and, more importantly, create a huge chemical space for drug discovery and development. The duplicated gene copies could explain the diversification processes of the multigene secondary metabolism pathways, such as those involved in the biosynthesis of terpenoids, 4 benzoxazinoids, 62 steroidal glycoalkaloids, 63 and glucosinolates. 64 More than 200,000 secondary metabolites have been found in angiosperms, many of which could stem from the genome-duplication-based rapid innovation of the complex traits. 48
Single-copy genes are common across angiosperm genomes. Based on 29 sufficiently high quality sequenced genomes, the large-scale identification and evolutionary characterization of single-copy genes from among multiple species is possible.
65
A significant negative correlation was found between the number of duplicate blocks and the number of single-copy genes. Only 17% of the single-copy genes are located in organelles, most of which are involved in binding and catalytic activity. Most single-copy genes are in nuclear genomes. Single-copy genes have a stronger codon bias than non-single-copy genes in eudicots.
65
The relatively high expression level of single-copy genes was partially confirmed by the RNA-Seq (transcriptome sequencing) data. Unlike in most other species, there is a strong negative correlation between
Transcriptome
The high cost of the whole-genome sequencing is still formidable. Accurate sequence assembly is still challenging, especially when the genome contains a high proportion of repeat sequences, high heterozygosity, and nondiploids.
2
RNA-Seq is a powerful tool for the assessment of gene expression and the identification and characterization of molecular markers in non-model organisms.
11
Unlike genome sequences, the intron sequences are not included in the RNA-Seq dataset, and the Unigene (contig) assembly is not disturbed by the repeat sequences and the ploidy level. A global view of the ethnomedicine resources and accurate delimitation of the novel medicinal taxa cannot be achieved without the molecular phylogeny based on the complete taxon sampling of the relevant tribes/genera. Because of the plummeting cost of RNA-Seq, dense taxon sampling is now possible in phylotranscriptomic studies. It is obvious that large-scale comparative transcriptome studies, including those of medicinal plants, are more feasible than comparative genomics based on the whole-genome sequencing. As shown in the NCBI PubMed, SRA, and GEO databases, transcriptomes of hundreds of medicinal plants have been sequenced, eg, Caryophyllales,
66
Fabaceae,
67
Reconstructing the origin and evolution of land plants and their algal relatives is a vital problem in plant phylogenetics and is essential for understanding how novel adaptive traits, eg, secondary metabolites, arose. Despite advances in molecular systematics, some evolutionary relationships remain poorly resolved. Inferring deep phylogenies with rapid diversification is often tricky, and genome-scale data significantly increase the number of informative characters for analyses. Since sparse taxon sampling could result in inconsistent results, transcriptome data of 92 streptophyte taxa were generated and analyzed along with 11 published plant genome sequences. 72 Phylogenetic reconstructions were conducted using 852 nuclear genes and 1,701,170 aligned sites. Robust support for a sister-group relationship between land plants and one streptophyte green algae, the Zygnematophyceae, was obtained. Strong and robust support for a clade comprising liverworts and mosses contradicts the widely accepted view of early land plant evolution. Phylogenetic hypotheses could be tested using the phylotranscriptomic approach to give deeper insights and novel arguments into the evolution of fundamental plant traits, including their fascinating chemodiversity.
Transcriptome sequencing also sheds light on other untapped issues of plant evolution. Arbuscular mycorrhizae (AM) are symbiotic systems in nature and have great significance in promoting the growth and stress resistance of medicinal plants.
73
AM have multifaceted effects on the active ingredients of TCM plants. The transcriptomes of nine phylogenetically divergent non-AM symbiosis plants were analyzed to reveal the correlation between the loss of AM symbiosis and the loss of many symbiotic genes,
74
which was found in four additional plant lineages besides the
Evolution and population genetics/genomics
SSRs play a major role as molecular markers for genome analysis and plant breeding. The microsatellites existing in the complete genome sequences would have a direct role in the genome organization, recombination, gene regulation, quantitative genetic variation, and evolution of genes. Microsatellite markers have been characterized for many medicinal plant families and genera, eg, Acanthaceae family,
77
Both ISSR
81
and SRAP markers were suitable for discriminating among the studied individuals, but the SRAP markers were more efficient and preferable.
78
Multiple regression analysis revealed statistically significant association between rust resistance and some molecular markers, which can provide clues for the identification of the individuals with higher rust resistance. RAPD (randomly amplified polymorphic DNA) and ISSR markers were used to characterize
SNPs (single nucleotide polymorphisms) are much more abundant than SSRs in most species,
84
including medicinal plants. The mutation rate of SNPs (10–9 per locus per generation) is much lower than that of SSRs (10–3–10–4).
85
Generally, there are only two alleles in each SNP site, whereas there can be more than 10 alleles in each SSR. The highly polymorphic SSRs are especially suitable for detecting the hybridization between closely related species and studying the gene flow/introgression.
86
SSRs are of lower ascertainment bias and are also good for studying the recent population structure. Mining suitable SSR sites via transcriptome sequencing datasets is fast and affordable. For example, 3,446 microsatellites were identified from 2718 Unigenes (16.8% of 16,142 assembled sequences) of the

SSRs predicted from the
NGS toolkits could provide grist for the medicinal plant phylogeography mill. Sufficiently abundant SNPs could be identified directly from the genome sequences of the model plants. Most medicinal plants lack genomic data; therefore two alternative strategies can be adopted. The faster and cheaper one is mining suitable SNP sites via transcriptome sequencing datasets. 11 However, the subsequent PCR primer design might not be successful, as no information about the intergenic sequences and the introns is available from the RNA-Seq data. On the other hand, large amounts of SNPs can be obtained by the simplified genome sequencing, mainly referring to RAD-Seq 50 and genotyping-by-sequencing (GBS), 88 although their reproducibility and reliability need further improvements.
Plants of various evolutionary levels, not only higher plants, are harnessed in TCM and ethnomedicine worldwide. The caterpillar fungus
Population genetics can be upgraded to population genomics using the large dataset of transcriptomes from multiple species.
68
The dearth of extant asexual species might be partially caused by the buildup of harmful mutations and intensified elimination risk linked with repressed recombination and segregation in these species, which was tested with a dataset of 62 transcriptomes of 29
Mechanisms of Species Evolution and Diversification
The incidence of polyploidy in land plant evolution has led to an acceleration of genome variations compared with other crown eukaryotes and is connected with key innovations in plant evolution. 67 Increasing genome resources facilitate linking genomic alterations to the origins of novel phytochemical and physiological features of medicinal plants. Ancestral gene contents for key nodes of the plant family tree are inferred. 90 The ancestral WGDs (whole-genome duplications) concentrating ~319 and 192 million years ago expedited the diversification of regulatory genes vital to seed and flower development, and were responsible for key innovations followed by the upsurge and ultimate supremacy of seed plants and flowering plants. 1 Widespread polyploidy in angiosperms might be the major factor generating novel genes and expanding some gene families. 64 However, most gene families lose most duplicated copies in a nearly neutral process, and a few families are actively selected for single-copy status. It is challenging to link genome modifications to speciation, diversification, and the phytochemical and/or physiological innovations that jointly comprise biodiversity and chemodiversity. Ongoing evolutionary genomics investigation may greatly improve the resolution, enabling the identification of specific genes responsible for particular innovations. More concise understanding of plant evolution may enrich fundamental knowledge of botanical diversity, including medicinally important traits that sustain humanity.
Case studies are important to illustrate the correlation between WGD and the diversification of secondary metabolism pathways. WGD and the tandem duplication facilitated glucosinolate pathway diversification in the mustard family (Brassicaceae) (Fig. 5).
64
In

Duplicate distribution among
Besides polyploidy, allopatric divergence, climatic oscillation-based divergence, hybridization and introgression, and pollination-mediated isolation are also highlighted as the mechanisms of medicinal species evolution, especially in the hotspot area of biodiversity, such as QTP. 91 Rapid species diversification followed the extensive uplift of QTP brought about numerous morphologically and phytochemically distinct species. Both morphological and metabolic phenotype innovations are apparently ecologically adaptive, and the underlying molecular mechanisms are still elusive.
Phenotype Evolution and Ecology
Medicinal plants synthesize an arsenal of protective molecules, most of which are secondary metabolites, can be ingested by animals and humans, and then help them antagonize against disadvantageous environmental conditions.
92
The epidemiological (parasite prevalence and virulence) and environmental (medicinal plant toxicity and abundance) conditions that predict the evolution of genetically fixed versus phenotypically plastic forms of animal medication could be identified using the tritrophic interaction between the monarch butterfly, its protozoan parasite, and its food plant
Numerous botanical compounds, as the integral part of plant defense mechanisms, also bind and modify fundamental regulators of animal physiological processes in ways that enhance animal adaptation to the ever-changing environments. 94 The underlying mechanism might be that animals and fungi, as heterotrophs, are capable of sensing chemical signals produced by plants and responding actively to the biotic/abiotic stress (xenohormesis). 95 These plant-derived cues offer early warning about fading ecological circumstances, permitting the heterotrophs to get ready for misfortune when conditions are still favorable. Plant secondary metabolites could activate the evolutionarily conserved cellular stress response and subsequently enhance the cellular adaptation to adversity in both plants themselves and animals that consume them. Xenohormesis could explain TCM pharmacological effects from an evolutionary and ecological perspective. 96 Medicinal herb, microbial, and human cellular signal transduction pathways have many conserved similarities, enabling beneficial effects of botanical metabolites in humans via a process of “cross-kingdom” signaling. 94
Daodi medicinal material (geoherb) is produced in particular geographic regions, where there is defined ecological environment and cultivation pipeline.
56
The clinical efficacy of a geoherb is superior to that of the same medicinal plant growing in other regions. The special medicinal features of a plant are determined by its genome, while the proper ecological conditions have major effects on the formation of a geoherb. For instance, Zhejiang, China, is the best production area of the geoherb Bai Shao (
The section
With the surge in NGS technology, it is becoming common to perform the phylogenetic study based on genomic data. However, for most medicinal plants it is not realistic to rely on the whole-genome sequencing data. RAD-Seq is easily applied to non-model plants for which no reference genome is available (Fig. 1),
50
and it is promising for reconstructing phylogenetic relationships in evolutionarily younger clades in which sufficient numbers of orthologous restriction sites are retained across species.
17
Coincidentally, the younger clades are more capable of harboring a wider variety of secondary metabolites, as chemodiversity often accompanies the rapid radiation and diversification. The evolutionarily young
Pharmacophylogeny vs Pharmacophylogenomics
Diverse new terms are emerging in the genomic era, such as phylogenomics, pharmacophylogenomics, and phylotranscriptomics, which are somewhat overlapping with pharmaphylogeny (pharmacophylogeny/pharmacophylogenetics). 48 Phylogenomics is the crossing of evolutionary biology and genomics, in which genome data are utilized for evolutionary reconstructions. Pharmaphylogeny, advocated by Peigen Xiao since the 1980s,101,102 focuses on the phylogenetic relationship of medicinal plants and aims to foster the sustainable utilization of TCM resources, and is thus nurtured by molecular phylogeny, chemotaxonomy, ethnopharmacology, and bioactivity studies (Fig. 6). Phylogenomics can be integrated into the pipeline of drug discovery and development, and extends the field of pharmaphylogeny at the omic level; thus the concept of pharmacophylogenomics, initially emphasizing the genomic analysis of the evolutionary history of drug targets, 103 could be redefined as an upgraded version of pharmaphylogeny.

Omics data that could be used in the pharmacophylogeny inference.
The new conceptual framework of pharmacophylogenomics highlights the comprehensive analysis of the evolutionary history of medicinal organisms (especially the predominant medicinal plants), in particular the congruence and conflict between molecular phylogeny and chemotaxonomy,46,47,51,52,100 the orthology and paralogy relationships,66,104 the degree and landscape of evolutionary transformation they have undergone, and the involved evolving metabolic pathways and regulatory networks. More specifically, first, the tree of life of different scales can be constructed based on the genomic information to determine the phylogenomic relationship of medicinal plant groups, eg, the relationship between the geo-herb (higher content of medicinal compounds and better therapeutic efficacy) 56 and non-geoherb populations; second, the genomic data, in particular those from the RAD-Seq or GBS, can be exploited to estimate the divergence time, reconstruct the geographic distribution, and infer the origin and the spatial distribution pattern of extant medicinal plants/geoherbs (Fig. 1)48,53; third, within the context of the temporal tree, the ecological factors, environmental attributes, and evolutionarily innovative traits can be combined to dissect the diversification process and mechanism of medicinal plants; fourth, the origin and structure of the phylogenetic diversity of medicinal plants could be revealed; fifth, the diversity of medicinal compounds could be dissected based on biodiversity to promote drug discovery via the high-throughput screening 105 ; last but not least, the dynamic alteration of the medicinal plant diversity can be predicted, and then the appropriate conservation and development strategies can be put forward.
During evolution, plants develop tactics of chemical defenses, leading to the evolution of specialized metabolites with diverse potencies. A correlation between phylogeny and biosynthetic pathways could offer a predictive approach, enabling more efficient selection of alternative and/or complementary plants for guaranteeing clinical use and novel lead discovery. This relationship has been rigorously tested and the potential predictive power subsequently validated.
106
A phylogenetic hypothesis was put forward for the medicinal plant subfamily Amaryllidoideae (Amaryllidaceae) based on parsimony and Bayesian analysis of nuclear, cp, and mt DNA sequences of over 100 species.
106
It is interesting to test whether alkaloid diversity and activity in bioassays related to the central nervous system are significantly correlated with molecular phylogeny. Evidence for a significant phylogenetic signal in these traits has been found, but the effect is not strong. Several genera are non-monophyletic, highlighting the importance of using phylogeny for understanding character distribution. Lack of congruence between specialized metabolism and molecular phylogeny is not unusual,10,46,47,51,52,100 and the prominent factor is convergent evolution. Alkaloid diversity and
The correlation between the plant molecular phylogeny and therapeutic utility has been suggested.107–109 For instance, bulky, juicy leaves representative of medicinal aloes (Aloeaceae, Liliales) rose during the most recent expansion ~10 million years ago and are powerfully associated with the molecular phylogeny and correlated to the probability of a species being used for therapy. 109 A noteworthy, though feeble, phylogenetic hint is apparent in the remedial uses of aloes, signifying that their pharmaceutical properties do not arise stochastically across the clades of the evolutionary tree. The taxonomic clades included in native pharmacopoeias are indeed associated with certain disease groups, and ecology and angiosperm phylogeny, which could be the alternative and/or complementary for chemical kinship and convergence, to a certain extent explain the observed preference of the therapeutic use. For instance, evolutionarily related plants from New Zealand, Nepal, and the Cape of South Africa are used to combat diseases of the same therapeutic spaces, 108 which powerfully shows the self-determining discovery of the botanical value. A considerably greater fraction of recognized medicinal plants is present in these phylogenetic groups than in haphazard samples, suggesting that screening work should be focused on a subgroup of traditionally used plants that are more affluent in medicinal molecules. The phylogenetic/phylogenomic cross-cultural evaluations would invigorate the use of old-fashioned knowledge in bioprospecting. Statistical analysis of the ethnopharmacology data based on Chinese medicinal plants of Magnoliidae, 110 Hamamelidae, and Caryophyllidae 111 has been performed to summarize the distribution pattern of ethnomedicine uses across three subclasses. These nearly extinct traditional knowledge, collected nationwide during a TCM resources survey, lay the foundation for further quantitative correlation studies of molecular phylogeny and therapeutic efficacy.
Chinese medicinal material resource is the foundation of the development of TCM. In the study of sustainable utilization of TCM resource, adopting innovative theory and method to find new TCM resource is one of the hotspots and always highlighted. 53 Pharmacophylogeny interrogates the phylogenetic relationship of medicinal organisms (especially medicinal plants), as well as the intrinsic correlation of morphological taxonomy, molecular phylogeny, chemical constituents, and therapeutic efficacy (ethnopharmacology and pharmacological activity). This new discipline may have the power to change the way we utilize medicinal plant resources and develop plant-based drugs. Phylogenomics can be integrated into the flowchart of drug discovery and development, and extends the field of pharmacophylogeny at the omic level. Analogously, phyloproteomics can be used in the proteome-based phylogeny study 112 ; it can be used to examine the evolutionary relationship at the epigenomic level. 113 phylometagenomics is also applicable in the exploration of medicinal plant-associated microbiota. 114
Many medicinally important tribes and genera, such as

Cladogram of the Ranunculaceae tribe Delphinieae, according to Refs 52, 119.
Series
The morphology-based 11-series classification of section
Conclusion and Prospects
The trend of integrating genomics and evolution into studies of medicinal plants is perceivable, and therefore it is time to summarize the current progress in the relevant fields in order to make full use of evolutionary biology/genomics and revolutionize the roadmap of medicinal plant inquiries. This review gave a brief analysis of the association and the distinguishing features of the multifaceted medicinal plant evolution and genomics studies, in the context of the plant-based drug discovery and the sustainable utilization of traditional pharmaceutical resources. A phylogenetic approach along with transcriptomics and other omics has value for understanding the evolution of medicinal plants, and a stronger case for the utility of these methods for future identification of useful genes and/or taxa for medicinal use is warranted.
The research paradigm of medicinal plant genome and evolution is evolving, and the use of omics techniques is reshaping the landscape of this dynamic field. Genomics, transcriptomics, proteomics, metabolomics, and other omics platforms generate formidably large data, which cannot be used efficiently in probing plant genome and evolution without the aid of advancing bioinformatics. Medicinal plants evolve new traits to adapt to the changing environments and pave the road toward a better life for themselves, while both hypothesis-driven and big data-driven studies integrate herbal technology, biotechnology, and information technology to pave the road toward a healthier life for humans.
Author Contributions
Conceived the review: DCH, PGX. Analyzed data and wrote the manuscript: DCH. Provided some reference information and edited the manuscript: PGX. Both authors reviewed and approved the final manuscript.
